Crespo Abel, Meyers Caroline, Coelho Alberto, Yáñez Matilde, Fraiz Nuria, Sotelo Eddy, Maes Bert U W, Laguna Reyes, Cano Ernesto, Lemière Guy L F, Raviña Enrique
Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, 15782-Santiago de Compostela, España, Spain.
Bioorg Med Chem Lett. 2006 Feb 15;16(4):1080-3. doi: 10.1016/j.bmcl.2005.10.073. Epub 2005 Nov 14.
As part of the optimization process of the lead compound I a focussed library of diversely substituted pyridazin-3(2H)-ones containing a 3-oxo-3-phenylprop-1-en-1-yl or 3-phenylprop-2-enoyl fragment at position 5 has been obtained and evaluated as antiplatelet agents. The structural modification at positions 2, 6 and 4 of the heterocyclic moiety allowed us to obtain preliminary information on the structure-activity relationship in this family.
作为先导化合物I优化过程的一部分,已获得了一个聚焦库,该库包含在5位含有3-氧代-3-苯基丙-1-烯-1-基或3-苯基丙-2-烯酰基片段的各种取代的哒嗪-3(2H)-酮,并作为抗血小板剂进行了评估。杂环部分2、6和4位的结构修饰使我们能够获得关于该家族构效关系的初步信息。